Innoviva INVA
NASDAQ INVA
$21.33 -0.02 (-0.09%)
As of: Sep 4, 2026 · 3:59 PM EDT

Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017)

Innoviva's (INVA) quarterly Non-Current Deffered Revenue came in at $1.6 million in Q3 2017, down 36.3% YoY from $2.4 million in Q3 2016, and down 12.47% on a QoQ basis from $1.8 million in Q2 2017.

Analysis

Innoviva (INVA) Non-Current Deffered Revenue (2010 - 2017) Analysis & Trends

Innoviva (INVA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q3 2017.

  • Quarterly Non-Current Deffered Revenue fell 36.3% year-over-year to $1.6 million in Q3 2017, while the trailing twelve-month figure through Sep 2017 was $1.6 million (down 36.3% YoY) and the FY2016 annual result came in at $2.2 million, down 28.56% from the prior year.
  • Non-Current Deffered Revenue declined to $1.6 million in Q3 2017, from $1.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $5.7 million in Q1 2013 to a low of $13000.0 in Q2 2014.
  • A 5-year average of $2.8 million and a median of $2.7 million in 2016 frame the typical range for Non-Current Deffered Revenue.
  • Annual changes were most pronounced in 2014 — Non-Current Deffered Revenue sank 99.72% — and 2016, when it surged 3133.71%.
  • Tracing INVA's Non-Current Deffered Revenue over 5 years: stood at $5.5 million in 2013, then sank by 30.56% to $3.8 million in 2014, then slipped by 18.19% to $3.1 million in 2015, then decreased by 28.56% to $2.2 million in 2016, then declined by 29.95% to $1.6 million in 2017.
  • The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q3 2017), $1.8 million (Q2 2017), and $2.0 million (Q1 2017), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 147.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 Innoviva 1.56 Bn 984.81 Mn 90.62 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2017 1.55 Mn
Jun 30, 2017 1.77 Mn
Mar 31, 2017 1.99 Mn
Dec 31, 2016 2.21 Mn
Sep 30, 2016 2.44 Mn
Jun 30, 2016 2.66 Mn
Mar 31, 2016 2.88 Mn
Dec 31, 2015 3.10 Mn
Sep 30, 2015 3.32 Mn
Jun 30, 2015 3.54 Mn
Mar 31, 2015 3.76 Mn
Dec 31, 2014 3.79 Mn
Sep 30, 2014 4.06 Mn
Jun 30, 2014 4.33 Mn
Mar 31, 2014 5.25 Mn
Dec 31, 2013 5.46 Mn
Sep 30, 2013 5.15 Mn
Jun 30, 2013 5.75 Mn
Mar 31, 2013 5.67 Mn
Dec 31, 2012 6.01 Mn